• N Burioka, K Takano, E Hoshino, H Suyama, S Saito, and T Sasaki.
• Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan. burioka@grape.med.tottori-u.ac.jp
• Respiration. 1997 Jan 1; 64 (4): 268-72.

AbstractThe clinical utility of the newly developed pressure swing adsorption (PSA)-type oxygen concentrator with a membrane humidifier that does not require added water for humidification was evaluated in 13 patients with chronic pulmonary disease who were receiving long-term oxygen therapy. PaO2 and the relative humidity were measured when the patient breathed air and oxygen from the new device via a nasal cannula. After using the new concentrator for 5 h, the patients were asked whether they experienced dry nasal passages or a dry throat. A significant difference between the PaO2 measured while the patients breathed room air and while they breathed oxygen from the new device was observed. A significant difference was observed between the relative humidity of room air (44.7 +/- 18.6%) and that of the oxygen flow (72.7 +/- 14.8%) from the new device. None of the patients experienced dry nasal passages, dry throat, or any other adverse effects. Since this new PSA-type oxygen concentrator with a membrane humidifier supplies well-humidified nasal oxygen without water, laborious cleaning of the container and changing of the water are not necessary, and may help to improve the patient's quality of life.

19 keywords...

hide…